Biomarker and Pharmacologic Evaluation of the -Secretase Inhibitor PF-03084014 in Breast Cancer Models

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-1379
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Γ-Secretase Inhibitor Enhances Antitumour Effect of Radiation in Notch-Expressing Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2012English

LKB1, a New Biomarker in Breast Cancer

Journal of Cancer Therapy
2016English

Evaluation of FLT-PET-CT as an Imaging Biomarker of Proliferation in Primary Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2014English

Synthesis of SMO Inhibitor PF-04449913

Synfacts
2014English

The Therapy of Gefitinib Towards Breast Cancer Partially Through Reversing Breast Cancer Biomarker Arginine

African Health Sciences
Medicine
2015English

Breast Cancer Models

Nuclear Medicine Seminars
2019English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy